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SARS-CoV-2 infection-related health crisis has led to unfounded or exaggerated claims 20 
on treatments. One area of controversy has been the role and dose of vitamin D supplementation 21 
in COVID-191 2. Given the potential importance but prevailing uncertainty, the joint National 22 
Institute for Health and Care Excellence (NICE), Public Health England and Scientific 23 
Advisory Committee on Nutrition rapid guideline was recently published. It concluded that 24 
there was little evidence, highlighted the need for further research, and supported the existing 25 
government advice predicated on musculoskeletal health on vitamin D supplementation of 26 
400IU/day for adults and children between October and March, when people in the UK do not 27 
make sufficient vitamin D from sunlight. It also stressed that certain populations such as 28 
minority ethnic groups, should consider taking this dose throughout the year3. The guidance is 29 
timely, but questions remain.  30 
What is the evidence for a link between vitamin D and COVID-19? 31 
Vitamin D supplementation of 400-1000IU/day has a modest protective effect for acute 32 
respiratory infections4, providing indirect evidence for SARS-CoV-2 infection. There is, 33 
however, sparse research on a direct link.  34 
The NICE review included one small randomised controlled trial (RCT) for COVID-35 
19 treatment5, no RCTs for COVID-19 prevention, and 12 observational studies of associations 36 
between vitamin D status and COVID-19 incidence or treatment. Among 76 Spanish patients 37 
hospitalised with COVID-19, high-dose supplementation equivalent to 21,280IU 38 
cholecalciferol on admission day and 10,640IU on day 3 and 7, then weekly until discharge 39 
reduced disease severity5. We found two further RCTs with conflicting findings. Among 240 40 
Brazilian hospitalised patients with COVID-19, a single oral vitamin D3 dose of 200,000IU 41 
versus placebo did not reduce the hospital length of stay6. In contrast, in 40 Indian SARS-CoV-42 
2 positive Indians, infection vitamin D 60,000IU daily for 7 days, followed by the same dose 43 
either weekly or daily led to greater negative tests at 21 days7. These discrepancies highlight 44 
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the challenges of RCT design, with varying selection criteria, initial vitamin D status, the type, 45 
dose, and duration of supplementation, the endpoints studied, and risk of bias and study quality. 46 
The observational evidence is inconsistent with some, but not all, studies reporting an 47 
association between vitamin D insufficiency and SARS-CoV-2 infection3 8. However, the 48 
observed link could be attributed to several confounding factors including age9, ethnicity10, 49 
genetic heterogeneity11, and obesity12 13 which are incompletely or not accounted for in 50 
different studies.  51 
High-quality evidence is currently lacking, but there is suggestive evidence for an 52 
immunomodulatory role of vitamin D for respiratory infections and contextual evidence of the 53 
shared risk factors between vitamin D deficiency and COVID-19 severity: older age, obesity, 54 
and minority ethnicity. There is also a correlation between seasonal decline of vitamin D and 55 
higher COVID-19 burden in high-latitude countries14. The available evidence cannot be 56 
ignored and makes a compelling case for further research. 57 
What next with the UK guidance on use of vitamin D supplementation? 58 
The recommendation of 400IU seems justifiable to maintain 25(OH)D levels >25nmol/l 59 
in 97.5% of the UK population, but it is unclear whether this level is appropriate for 60 
immunomodulatory actions for COVID-19. Guidance recommending 400IU/day vitamin D 61 
supplementation in the UK has been in existence for a while, but its implementation has not 62 
been ensured. Raising awareness of the relevance of vitamin D is therefore appropriate for 63 
musculoskeletal health, particularly during lockdowns. It may also be relevant for COVID-19, 64 
given the suggestive though not conclusive evidence of its potential role and the precautionary 65 
principle. We also need clear guidance on how to obtain vitamin D for vulnerable groups. 66 
Health care professionals can point people to the free NHS vitamin D supplement provisions 67 
for people at high risk15 and for women and children who qualify for the Healthy Start scheme. 68 
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Clinicians also need to be aware that vegetarians or vegans would need guidance on appropriate 69 
sources of vitamin D supplements.  70 
The public health emergency posed by COVID-19 demands the use of all promising 71 
solutions, therefore vitamin D remains a plausible candidate. However, policy 72 
recommendations need to ensure that the public are not falsely reassured regarding the role of 73 
vitamin D for COVID-19. These guidelines therefore must be accompanied with continued 74 
messaging on hand hygiene, face coverings, physical distancing, and the importance of vaccine 75 
uptake in culturally and linguistically adapted campaigns through local community groups.  76 
The published guidelines have clearly articulated the currently unconvincing evidence 77 
of vitamin D for COVID-19; therefore, it is vital that ongoing and future trials evaluate the 78 
effect of vitamin D supplementation with improved design including attention to comparing 79 
different dosing regimens, initial vitamin D status, inclusion of different population subgroups, 80 
older participants and those with morbidities, and in settings including hospitalised patients 81 
and population-based samples. Ongoing trials such as COVIT-TRIAL16 and CORONAVIT 82 
(NCT04579640), which is comparing the national recommendation with higher dosage 83 
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